<PAGE> 1
HYPERTENSION DIAGNOSTICS, INC.
FOR IMMEDIATE RELEASE
Contact: Greg H. Guettler
President
(651) 687-9999
HYPERTENSION DIAGNOSTICS EXPECTS A SIGNIFICANT INCREASE
IN FISCAL YEAR 2001 REVENUE
ST. PAUL, MN, November 8, 2000 - Hypertension Diagnostics, Inc. (NASDAQ
SmallCap: HDII; HDIIW; HDIIU), today announced it expects to see a significant
increase in revenue for the fiscal year ending June 30, 2001. Sales of the
Company's HDI/PulseWave(TM) CR-2000 Research CardioVascular Profiling System are
expected to contribute more than $1.5 million to fiscal year 2001 revenue.
Revenue from sales of HDI's CR-2000 Research System to international customers,
domestic customers and to major pharmaceutical companies for several multi-site
clinical research studies are expected to more than triple the total fiscal year
2000 revenue of $423,490. The recently announced clearance received from the
U.S. Food and Drug Administration (FDA) to market the CVProfilor(TM) DO-2020
Cardiovascular Profiling System for use by physicians and other health care
providers has not been factored into this revenue estimate. The Company's FDA
clearance was contingent upon certain requests and requirements which were
negotiated by HDI and which may require about eight weeks to fully implement
before the product may be released to the marketplace.
During fiscal year 2000, three pharmaceutical firms began using the
HDI/PulseWave(TM) CR-2000 Research CardioVascular Profiling System in their
multi-site clinical research trials. Then, during the first four months of
fiscal year 2001, two additional pharmaceutical firms also selected the CR-2000
Research System for their multi-site clinical research trials, bringing the
total number of drug manufacturers employing HDI's technology to five including:
Alteon, Inc.; AstraZeneca, LP; Parke-Davis; Pfizer, Inc. and Solvay
Pharmaceuticals, Inc. The Company's patented and proprietary vascular profiling
technology is also being used by the National Institutes of Health/National
Heart, Lung, and Blood Institute (NIH/NHLBI) for their Multi-Ethnic Study of
Atherosclerosis ("MESA") research trial - a prospective clinical study
attempting to
- more -
<PAGE> 2
Page 2, Hypertension Diagnostics, Inc.
November 8, 2000
identify clinical markers or parameters for predicting cardiovascular disease.
The MESA trial is planned to be a 10-year investigation of more than 6,000 men
and women in the U.S.
Global interest in the HDI/PulseWave(TM)CR-2000 Research System has
grown substantially during the last fiscal year. The CR-2000 Research System is
now being utilized by physicians and researchers in 16 countries throughout the
world. These System users have contributed more than 20 new scientific
publications to HDI's bibliography of more than 95 scientific and clinical
abstracts and articles. The Company believes that these references strongly
reinforce the scientific and clinical merit of the Company's arterial waveform
analysis methodology, they help to expand the awareness for the CR-2000 Research
System, and they broaden the understanding and clinical application for small
artery elasticity as an early and sensitive marker for vascular disease.
Forward-looking statements in this press release are made under the
safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
The Company wishes to caution readers not to place undue reliance on any
forward-looking statements and to recognize that the statements are not
predictions of actual future results. Actual results could differ materially
from those presented and anticipated in the forward-looking statements due to
the risks and uncertainties set forth in the Company's 2000 Annual Report on
Form 10-KSB under the caption "Risk Factors", as well as others not now
anticipated.
# # #
Hypertension Diagnostics, HDI/PulseWave and CVProfilor are trademarks of
Hypertension Diagnostics, Inc. All rights reserved.
Website: www.hdi-pulsewave.com
